In today’s briefing:
- #116 India Insight: US Crude Exports to India Rise, Zomato Faces Probe, Reliance Cuts Jobs Pre-IPO
- Looking to Dodge U.S. Tariffs, Chinese Manufacturers Set Up Shop in Southeast Asia
- APAC Healthcare Weekly (Mar 9)- Daiichi Sankyo, Kyorin Pharma, Celltrion, Zydus Lifesciences, Biocon
#116 India Insight: US Crude Exports to India Rise, Zomato Faces Probe, Reliance Cuts Jobs Pre-IPO
- U.S. crude exports to India hit a two-year high as refiners shift supply amid stricter sanctions on Russian oil shipments.
- Zomato (ZOMATO IN) , Swiggy (SWIGGY IN) , and Zepto face an antitrust probe over deep discounting, as local retailers allege unfair competition in India’s quick commerce sector.
- Reliance Retail tightens operations, cuts jobs, and limits expansion to boost valuations ahead of IPO, as market concerns impact investor sentiment.
Looking to Dodge U.S. Tariffs, Chinese Manufacturers Set Up Shop in Southeast Asia
A growing number of Chinese manufacturers have set up factories in Southeast Asia, hoping to use the region to bypass U.S. import controls as the Trump administration plans to slap additional tariffs on Chinese goods.
Whether this approach will work, however, remains to be seen as Washington may tighten its scrutiny over Chinese companies registered overseas.
In 2024, the industrial parks that Amata Corp. PCL operates in Southeast Asia attracted nearly 90 foreign-funded factories, 75% of which were from China, Amata Chairman Vikrom Kromadit said in a recent interview with Caixin.
APAC Healthcare Weekly (Mar 9)- Daiichi Sankyo, Kyorin Pharma, Celltrion, Zydus Lifesciences, Biocon
- Daiichi Sankyo announced positive topline result from the phase 3 trial of Enhertu in gastric cancer. Kyorin Pharmaceutical outlicensed KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous urticaria, to Novartis.
- Celltrion received FDA approval for Stoboclo and Osenvelt, biosimilars referencing Prolia and Xgeva, respectively. Zydus Lifesciences expects to start the development of world’s first combination vaccine against shigellosis and typhoid.
- Biocon received FDA approval for lenalidomide capsules, indicated for types of multiple myeloma, and some other hematologic indications and dasatinib tablets for the treatment of chronic myeloid leukemia.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
